Eye Co Pty Ltd

ABN: 22 109 283 892

1st November 2021

Eye Co Announces Completion of Phase 1b Safety Study

Eye Co is very pleased to announce the successful completion of its Phase 1b safety study involving its cornerstone technology, intravitreal **Fludrocortisone Acetate**.

This study involved patients with late-stage dry Age-Related Macular Degeneration (d-AMD) and represented the first time this drug has been used in human subjects with retinal disease.

The study concluded that there was **no evidence of any adverse events**, either ocular or systemic. There was also no evidence of intraocular pressure spikes or cataract development commonly associated with products injected into the eye. Subjects involved in the study were each monitored for a period of 5 months following the injection.

Fludrocortisone Acetate is a potential breakthrough treatment for Geographic Atrophy (GA) associated with the dry form of AMD for which no treatment is currently available. The drug also has significant potential in the treatment of other major retinal diseases.

A series of patent claims were recently granted by the Australian Patent Office for the use of **Fludrocortisone Acetate** in the treatment of Geographic Atrophy (GA). The patent also covers combinational use with anti-VEGF medications. Applications for these patent claims are currently under evaluation in other key jurisdictions including USA, Europe, and Asia Pacific.

The recently announced publication of a pre-clinical study in the **Journal of Experimental Eye Research**, titled:

> *"Anti-inflammatory and neuroprotective properties of the corticosteroid fludrocortisone in retinal degeneration"*

provides further confirmation of the effectiveness of **fludrocortisone** in the treatment of macular atrophy associated with **dry Macular Degeneration** in animal models.

Efficacy studies in Diabetic Macular Oedema unresponsive to anti-VEGF medications and in early dry macular degeneration are scheduled to commence from early 2022.

Peter Abrahamson
Managing Director